Association of XRCC2 Rs3218536 Polymorphism with Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2017 Jul 28

PMID 28749098

Citations 18

Authors

Mahdieh Kamali

Sedigheh Hamadani

Hossein Neamatzadeh

Mahta Mazaheri

Masoud Zare Shehneh

Mitra Modaress Gilani

Fatemeh Haghighi

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have investigated the association of X-Ray Repair Cross-Complementing Group 2 (XRCC2) rs3218536 polymorphism with breast and ovarian cancer. However, this association remains conflicting. Therefore, we have performed the current systematic review and meta-analysis to clarify the association between XRCC2 rs3218536 polymorphism with risk of breast and ovarian cancer. Methods: We conducted a search in PubMed, Google Scholar and ISI Web of Science to select relevant studies on the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. We calculated the odds ratios (OR) and 95% confidence intervals (CI) for five genetic contrasts. In addition, a stratified analysis was conducted cancer type, ethnicity and HWE status. Results: A total of 17 studies with 5694 cases and 6450 controls for breast cancer and nine case-control studies with 4464 cases and 6353 controls for ovarian cancer were identified for the analysis of the association with XRCC2 rs3218536 polymorphism. The pooled ORs revealed that XRCC2 rs3218536 polymorphism was associated with breast cancer under the heterozygote contrast (AG vs. GG: OR = 0.929, 95% CI = 0.873-0.987, p=0.018) and ovarian cancer under dominant contrast (AA+AG vs. GG: OR = 0.725, 95% CI = 0.537-0.979, p=0.036) in the overall population. The stratified analysis indicated a significant association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer risk among Caucasians. Conclusion: Inconsistent with previous meta-analysis, this meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer risk in overall population, especially among Caucasians.

Citing Articles

Association of the CXCL12 rs1801157 Polymorphism with Breast Cancer Risk: A Meta-Analysis.

Alijanpour A, Golshan A, Vakili-Ojarood M, Shirinzadeh-Dastgiri A, Naseri A, Karimi-Zarchi M Asian Pac J Cancer Prev. 2024; 25(3):767-776.

PMID: 38546059 PMC: 11152371. DOI: 10.31557/APJCP.2024.25.3.767.

Association between XRCC2 Arg188His Polymorphism and Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.

Dastgheib S, Sayad S, Azizi S, Hajizadeh N, Asadian F, Karimi-Zarchi M Asian Pac J Cancer Prev. 2024; 25(1):43-55.

PMID: 38285766 PMC: 10911734. DOI: 10.31557/APJCP.2024.25.1.43.

Impact of Interaction between Single Nucleotide Polymorphism of XRCC1, XRCC2, XRCC3 with Tumor Suppressor Tp53 Gene Increases Risk of Breast Cancer: A Hospital Based Case-Control Study.

Datkhile K, Gudur R, Bhosale S, Durgawale P, Jagdale N, More A Asian Pac J Cancer Prev. 2023; 24(9):3065-3075.

PMID: 37774058 PMC: 10762731. DOI: 10.31557/APJCP.2023.24.9.3065.

Association of XRCC3 18067 C>T (Thr241Met) polymorphism with risk of cervical and ovarian cancers: A systematic review and meta-analysis.

Karimi-Zarchi M, Moghimi M, Abbasi H, Hadadan A, Tabatabaei R, Javaheri A Interv Med Appl Sci. 2022; 11(3):172-181.

PMID: 36343295 PMC: 9467339. DOI: 10.1556/1646.11.2019.21.

Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.

Li Y, Liu X, Chang Y, Fan B, Shangguan C, Chen H Biomed Res Int. 2022; 2022:2645090.

PMID: 36281462 PMC: 9587677. DOI: 10.1155/2022/2645090.

References

Qureshi Z, Mahjabeen I, Baig R, Kayani M . Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in Pakistan. Asian Pac J Cancer Prev. 2015; 15(23):10225-9. DOI: 10.7314/apjcp.2014.15.23.10225. View

Brooks J, Shore R, Zeleniuch-Jacquotte A, Currie D, Afanasyeva Y, Koenig K . Polymorphisms in RAD51, XRCC2, and XRCC3 are not related to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008; 17(4):1016-9. DOI: 10.1158/1055-9965.EPI-08-0065. View

Smolarz B, Makowska M, Samulak D, Michalska M, Mojs E, Wilczak M . Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and triple-negative breast cancer in Polish women. Clin Exp Med. 2014; 15(2):151-7. PMC: 4544483. DOI: 10.1007/s10238-014-0284-7. View

Shiryazdi S, Kargar S, Nasaj H, Neamatzadeh H, Ghasemi N . The accuracy of Breastlight in detection of breast lesions. Indian J Cancer. 2016; 52(4):513-6. DOI: 10.4103/0019-509X.178389. View

Han J, Hankinson S, Ranu H, De Vivo I, Hunter D . Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study. Carcinogenesis. 2003; 25(2):189-95. DOI: 10.1093/carcin/bgh002. View

Stewart S, Lakhani N, Brown P, Larkin O, Moore A, Hayes N . Gynecologic cancer prevention and control in the National Comprehensive Cancer Control Program: progress, current activities, and future directions. J Womens Health (Larchmt). 2013; 22(8):651-7. PMC: 3736645. DOI: 10.1089/jwh.2013.4465. View

Shadrina A, Ermolenko N, Boyarskikh U, Sinkina T, Lazarev A, Petrova V . Polymorphisms in DNA repair genes and breast cancer risk in Russian population: a case-control study. Clin Exp Med. 2014; 16(1):21-8. DOI: 10.1007/s10238-014-0329-y. View

Neamatzadeh H, Shiryazdi S, Kalantar S . BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review. J Res Med Sci. 2015; 20(3):284-93. PMC: 4468235. View

Webb P, Hopper J, Newman B, Chen X, Kelemen L, Giles G . Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):319-23. DOI: 10.1158/1055-9965.EPI-04-0335. View

10.

Rafii S, ORegan P, Xinarianos G, Azmy I, Stephenson T, Reed M . A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet. 2002; 11(12):1433-8. DOI: 10.1093/hmg/11.12.1433. View

11.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

12.

Michalska M, Samulak D, Romanowicz H, Jablonski F, Smolarz B . Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and ovarian cancer in Polish women. Exp Mol Pathol. 2016; 100(2):243-7. DOI: 10.1016/j.yexmp.2016.01.007. View

13.

He Y, Zhang Y, Jin C, Deng X, Wei M, Wu Q . Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis. PLoS One. 2014; 9(3):e91202. PMC: 3951328. DOI: 10.1371/journal.pone.0091202. View

14.

Jafari Nedooshan J, Forat Yazdi M, Neamatzadeh H, Shehneh M, Kargar S, Seddighi N . Genetic Association of XRCC1 Gene rs1799782, rs25487 and rs25489 Polymorphisms with Risk of Thyroid Cancer: a Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2017; 18(1):263-270. PMC: 5563111. DOI: 10.22034/APJCP.2017.18.1.263. View

15.

Mohamed F, Hussien Y, AlBakry M, Mohamed R, Said N . Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility. Mol Biol Rep. 2013; 40(5):3757-68. DOI: 10.1007/s11033-012-2452-8. View

16.

Garcia-Closas M, Egan K, Newcomb P, Brinton L, Titus-Ernstoff L, Chanock S . Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet. 2006; 119(4):376-88. DOI: 10.1007/s00439-006-0135-z. View

17.

Loizidou M, Michael T, Neuhausen S, Newbold R, Marcou Y, Kakouri E . Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. Breast Cancer Res Treat. 2008; 112(3):575-9. DOI: 10.1007/s10549-007-9881-4. View

18.

Sobhan M, Forat Yazdi M, Mazaheri M, Shehneh M, Neamatzadeh H . Association between the DNA Repair Gene XRCC3 rs861539 Polymorphism and Risk of Osteosarcoma: a Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2017; 18(2):549-555. PMC: 5454757. DOI: 10.22034/APJCP.2017.18.2.549. View

19.

Forat-Yazdi M, Neamatzadeh H, Sheikhha M, Zare-Shehneh M, Fattahi M . BRCA1 and BRCA2 common mutations in iranian breast cancer patients: a meta analysis. Asian Pac J Cancer Prev. 2015; 16(3):1219-24. DOI: 10.7314/apjcp.2015.16.3.1219. View

20.

Kuschel B, Auranen A, McBride S, Novik K, Antoniou A, Lipscombe J . Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002; 11(12):1399-407. DOI: 10.1093/hmg/11.12.1399. View